|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM274071363 |
| 003 |
DE-627 |
| 005 |
20231225002648.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2017 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1021/acs.langmuir.7b00742
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0913.xml
|
| 035 |
|
|
|a (DE-627)NLM274071363
|
| 035 |
|
|
|a (NLM)28732161
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Landarani-Isfahani, Amir
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Elegant pH-Responsive Nanovehicle for Drug Delivery Based on Triazine Dendrimer Modified Magnetic Nanoparticles
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 16.01.2019
|
| 500 |
|
|
|a Date Revised 16.01.2019
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Owing to properties of magnetic nanoparticles and elegant three-dimensional macromolecule architectural features, dendrimeric structures have been investigated as nanoscale drug delivery systems. In this work, a novel magnetic nanocarrier, generation two (G2) triazine dendrimer modified Fe3O4SiO2 magnetic nanoparticles (MNP-G2), was designed, fabricated, and characterized by Fourier transform infrared (FT-IR), thermal gravimetric analysis (TGA), vibrating sample magnetometer (VSM), field emission scanning electron microscopy (FE-SEM), transmission electron microscopy (TEM), and dynamic light scattering (DLS). The prepared MNP-G2 nanosystem offers a new formulation that combines the unique properties of MNPs and triazine dendrimer as a biocompatible material for biomedical applications. To demonstrate the potential of MNP-G2, the nanoparticles were loaded with methotrexate (MTX), a proven chemotherapy drug. The MTX-loaded MNP-G2 (MNP-G2/MTX) exhibited a high drug-loading capacity of MTX and the excellent ability for controlled drug release. The cytotoxicity of MNP-G2/MTX using an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide based assay and MCF-7, HeLa, and Caov-4 cell lines revealed that MNP-G2/MTX was more active against the tumor cells than the free drug in a mildly acidic environment. The results of hemolysis, hemagglutination, and coagulation assays confirmed the good blood safety of MNP-G2/MTX. Moreover, the cell uptake and intracellular distribution of MNP-G2/MTX were studied by flow cytometry analysis and confocal laser scanning microscopy (CLSM). This research suggests that MNP-G2/MTX with good biocompatibility and degradability can be selected as an ideal and effective drug carrier in targeted biomedicine studies especially anticancer applications
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Dendrimers
|2 NLM
|
| 650 |
|
7 |
|a Drug Carriers
|2 NLM
|
| 650 |
|
7 |
|a Magnetite Nanoparticles
|2 NLM
|
| 650 |
|
7 |
|a Triazines
|2 NLM
|
| 650 |
|
7 |
|a Silicon Dioxide
|2 NLM
|
| 650 |
|
7 |
|a 7631-86-9
|2 NLM
|
| 700 |
1 |
|
|a Moghadam, Majid
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mohammadi, Shima
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Royvaran, Maryam
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Moshtael-Arani, Naimeh
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rezaei, Saghar
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tangestaninejad, Shahram
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mirkhani, Valiollah
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mohammadpoor-Baltork, Iraj
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Langmuir : the ACS journal of surfaces and colloids
|d 1992
|g 33(2017), 34 vom: 29. Aug., Seite 8503-8515
|w (DE-627)NLM098181009
|x 1520-5827
|7 nnns
|
| 773 |
1 |
8 |
|g volume:33
|g year:2017
|g number:34
|g day:29
|g month:08
|g pages:8503-8515
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1021/acs.langmuir.7b00742
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_721
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 33
|j 2017
|e 34
|b 29
|c 08
|h 8503-8515
|